Shiyao Group: Received a milestone payment of $10 million under the strategic research and development cooperation agreement with AstraZeneca.

Stone Pharmaceuticals Group announced that the company previously disclosed on June 13, 2025, that it had signed a strategic research and development cooperation agreement with AstraZeneca to discover and develop new oral small molecule candidate drugs. The company has received a milestone payment of $10 million from AstraZeneca on August 5, 2026, for exercising one of the PCC project options under the terms of the agreement, marking that the relevant research and development work under this agreement is steadily progressing as planned.